Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254474 | 1.00 | POLB (0.48) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL92404 | 0.89 | NR4A1 (0.50) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL14254478 | 0.89 | CHRNB2 (0.48) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL14254475 | 0.88 | CHRNB2 (0.46) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL12327761 | 0.81 | CHRNB2 (0.46) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL85313 | 0.81 | KCNH2 (0.46) | CHRNB2CHRNA5CHRNA7CHRNA4LMNA | |
| SCHEMBL26714275 | 0.80 | POLB (0.55) | POLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL31722127 | 0.80 | POLB (0.55) | POLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL12327950 | 0.80 | CHRNB2 (0.45) | POLBCHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL13032659 | 0.80 | POLB (0.57) | POLBLMNAKDM4ESMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | POLB 3346/4885CHRNB2 3019/4885CHRNA5 3021/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | POLB 3839/4885CHRNB2 3177/4885CHRNA5 2902/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | POLB 3232/4885CHRNB2 3512/4885CHRNA5 3488/4885 |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | POLB 1369/4885CHRNB2 4677/4885CHRNA5 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.